Facebook
Twitter
LinkedIn
ForwardPark City Myeloma and Lymphoma Summit
This CME-accredited activity, Park City Myeloma and Lymphoma Summit, features leading experts in hematologic malignancies who will provide a comprehensive overview of current and emerging strategies for the management of multiple myeloma, lymphoma, and Waldenström Macroglobulinemia.
This activity aims to improve learners' knowledge and competence to apply practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients with hematologic malignancies. The program features in-depth discussion and analysis of the latest scientific findings and practice-changing advances in newly diagnosed and relapsed multiple myeloma and lymphomas with a focus on emerging immunotherapies, including but not limited to CAR-T therapy and T-cell redirecting bispecific antibodies. Expert faculty will aim to place the role of different therapeutic agents in clinical contexts and discuss how to utilize these therapeutic options to effectively contribute to patient care.
Target Audience
Cancer care professionals
Practicing medical oncologists/hematologists
- Radiation oncologists
Pathologists
Medical oncology and hematology fellows
Oncology nurses
Nurse practitioners
Physician assistants
Pharmacists
ORGANIZING COMMITTEE:
Course Director:
Binay Shah, MD, MHA - Binaytara Foundation
Conference Co-Chairs:
Douglas Sborov, MD, MS - Huntsman Cancer Institute - Cancer Research North
Lindsey A. Fitzgerald, MD - Huntsman Cancer Institute - Cancer Research North
Bradley Hunter, MD, MPH - Intermountain Health LDS Hospital
Learning Objectives
Upon successful completion of this educational activity, participants will be able to:
- Review strategies for induction and treatment for both transplant-eligible and transplant-ineligible with newly diagnosed multiple myeloma
- Explain the management strategies for patients with 1-3 prior lines of therapy
- Describe indications and safety of CAR-T, bispecific antibodies MM, and lymphoma
- Interpret the evolving treatment strategies for the initial management of DLBCL
Parking
Parking is complimentary for all guests.
GLOBAL ONCOLOGY PROJECT
Click this link to learn more about our ongoing project building a 200-bed cancer hospital in Nepal: https://binayfoundation.org/cancer-hospital/
September 28th, 2024
All times are listed in Mountain Time (MT)
07:00 AM – 08:00 AM Registration, Breakfast, & Exhibits
08:00 AM – 08:05 AM Welcome
08:05 AM – 08:20 AM Addressing Global Cancer Health Disparities - Building a 200-Bed Cancer Hospital In Nepal - Justin Marquart
08:20 AM – 09:50 AM Session 1 - Multiple Myeloma (NDMM)
Session Chair: Douglas Sborov, MD, MS
08:20 AM – 08:30 AM Introduction: The Brave New World of Multiple Myeloma - Douglas Sborov, MD, MS
08:30 AM – 09:00 AM Newly Diagnosed Multiple Myeloma - Now We Know What We Thought We Knew - Dan Sherbenou, MD, PhD
09:00 AM – 09:10 AM Debate: Velcade vs. Carfilzomib as the PI of Choice - Prashant Sharma, MD & Amandeep Godara, MBBS
09:10 AM – 09:20 AM Debate: Autologous Transplant: Is There Still a Role? - Dane James Osborn, MD & Dan Sherbenou, MD, PhD
09:20 AM – 09:30 AM Debate: Single Agent Lenalidomide vs. Doublet Maintenance - Brian McClune, DO & Saurabh Zanwar, MBBS, MD
09:30 AM – 09:40 AM Data in Perspective - Ryan E. Wilcox, MD
09:40 AM – 09:50 AM Q & A
09:50 AM – 10:10 AM Break & Exhibits
10:10 AM – 11:25 AM Session 2 - Multiple Myeloma (RRMM)
Session Chair: Douglas Sborov, MD, MS
10:10 AM – 10:35 AM Relapsed and Refractory Multiple Myeloma - Out with the Old, In with the New - Gliceida Galarza Fortuna, MD
10:35 AM – 10:45 AM Debate: Early CAR-T or Wait Until Later? - Brian McClune, DO & Prashant Sharma, MD
10:45 AM – 10:55 AM Debate: Bispecific or CAR-T First? - Dane James Osborn, MD & Shashank Cingam, MD
10:55 AM – 11:05 AM Debate: Reuse and Recycle - Saurabh Zanwar, MBBS, MD & Wayne D. Ormsby, MD
11:05 AM – 11:15 AM Data in Perspective- Ryan E. Wilcox, MD
11:15 AM – 11:25 AM Q & A
11:25 PM – 12:25 PM Session 3 - Lymphoma (CLL)
Session Chair: Allison M. Bock, MD
11:25 AM – 11:45 AM Management in the Era of Targeted Therapies - Daniel A. Ermann, MD
11:45 AM – 11:55 AM Debate: Acalabrutinib vs. Zanubrutinib - Boyu Hu, MD & Daniel A. Ermann, MD
11:55 AM – 12:05 PM Debate: 3L or Later?: Pirtobrutinib vs. CAR T-Cell - Deborah Stephens, DO & Bradley Hunter, MD
12:05 PM – 12:15 PM Data in Perspective - Rachel E. Hu, MD
12:15 PM – 12:25 PM Q & A
12:25 PM – 01:25 PM Lunch & Exhibits
Product Theater Sponsored by Johnson & Johnson in Overlook Restaurant
Topic: What's Next for Patients with 2L+ Relapsed or Refractory Multiple Myeloma
Speaker: Daanish Hoda, MD
* This is a non-CME activity *
01:25 PM – 02:45 PM Session 4 - Lymphoma (Novel Therapies in the Frontline Treatment of Lymphomas)
Session Chair: Lindsey A. Fitzgerald, MD
01:25 PM – 01:30 PM Introduction: Management of Lymphomas in the Era of Novel Therapies - Lindsey A. Fitzgerald, MD
01:30 PM – 01:55 PM Novel Therapies in cHL (S1826 data), MCL (TRIANGLE, Boven), DLBCL (POLARIX) - Rachel E. Hu, MD
01:55 PM – 02:05 PM Debate: Newer regimens: ANVD and BrECADD vs. Older regimens: AAVD and RATHL for Newly Diagnosed Advanced Stage cHL - Matthew Genyeh Mei, MD & Harsh Shah, DO
02:05 PM – 02:15 PM Debate: How Do We Use the TRIANGLE Study in MCL – Auto-Transplant vs. Not - Sagar S. Patel, MD & Michael Wang, MD
02:15 PM – 02:25 PM Debate: PolaRCHP vs. RCHOP for Advanced Stage DLBCL - Lindsey A. Fitzgerald, MD & Daniel R. Sims, DO
02:25 PM – 02:35 PM Data in Perspective - Xylina T. Gregg, MD
02:35 PM – 02:45 PM Q & A
02:45 PM – 03:00 PM Break & Exhibits
03:00 PM – 04:15 PM Session 5 - Lymphoma (Novel Therapies in Relapsed/Refractory Non Hodgkin Lymphomas)
Session Chair: Bradley Hunter, MD
03:00 PM – 03:25 PM Novel Therapies in Relapsed NHLs (CAR T, Bispecifics, Targeted Agents) - Bradley Hunter, MD
03:25 PM – 03:35 PM Debate: What First in Relapsed NHL – CAR T vs. Bispecific?- Joseph Maakaron, MD & Narendranath Epperla, MD, MS
03:35 PM – 03:45 PM Debate: Glofitamab vs. Epcoritamab in Rel DLBCL - Ahmad S. Halwani, MD & Allison M. Bock, MD
03:45 PM – 03:55 PM Debate: Best Targeted Regimen for LBCL Patients Ineligible for CAR T, AutoSCT – 2L Tafa/Len vs. Pola-BR - Boyu Hu, MD & Charalambos (Babis) Andreadis, MD
03:55 PM – 04:05 PM Data in Perspective - Stephen Spurgeon, MD
04:05 PM – 04:15 PM Q & A
04:15 PM Adjourn
Parking
Parking is complimentary for all guests.
IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:
All conflict of interest has been identified and mitigated for individuals in control of contents.
PLANNING COMMITTEE DISCLOSURE STATEMENT:
None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.
Binay Shah, MD, MHA
Lindsey Fitzgerald, MD
Bradley Hunter, MD. MPH
Douglas Sborov, MD MS
Allison Bock
Charalambos Andreadis, MD, MS
Allison Bock
Shashank Cingam
Rachel E Hu
Narendranath Epperla, MD, MS
Daniel Ermann, Medical Doctor
Gliceida Galarza Fortuna
Amandeep Godara, MD
Xylina Gregg, MD
Ahmad Halwani, M.D.
Boyu Hu
Joseph Maakaron, MD
Brian McClune, DO
Matthew Mei, MD
Wayne Ormsby, MD
Dane Osborn, MD
Sagar Patel, MD
Harsh Shah, D.O.
Prashant Sharma, MD, FACP
Dan Sherbenou
Dan Sims
Stephen Spurgeon, MD
Debbie Stephens, DO
Michael Wang
Ryan Wilcox, MD
Saurabh Zanwar, MBBS, MD
Available Credit
- 6.25 ABIM MOC IISuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.25 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
- 6.25 AMA PRA Category 1 Credit™The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 6.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 6.25 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
- 6.25 Nursing Contact HoursProvider approved by the California Board of Registered Nursing, Provider # CEP17035, for 6.25 Contact Hours.
If you are interested in exhibiting at this meeting, please visit our exhibit page here - https://education.binayfoundation.org/exhibit-information
Price
POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE:
All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place.
The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference. The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees.
If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.
Violating this policy will result in a fine equivalent to a general display fee for that conference.
NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:
If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:
- If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
- If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event.
- If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event.
Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.
CANCELLATION POLICY
You may cancel your enrollment at any time. Cancellation fees apply as below:
- 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
- No refunds will be issued if registration is canceled after that date.
No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.